BACKGROUND: Chagas' disease is caused by infection with the protozoan agent Trypanosoma cruzi. An estimated sixteen to eighteen million people are infected in Latin America. Outside of endemic regions, Chagas' disease may be transmitted through the transfusion of infected blood components, congenital infection and organ transplantation. We sought to determine the sero-prevalence of antibodies to T. cruzi in a community sample of Latin American refugees and immigrants to Canada. METHODS: This was a sero-prevalence study in Latin American refugees and immigrants living in Canada. Eligible subjects were born in South America, Central America or in Mexico. Participants were recruited from a variety of community settings, as well as from medical clinics. Serum was tested by enzyme-linked immunoassay for antibodies to T. cruzi. RESULTS: A total of 102 participants were enrolled. One sample tested positive for antibodies for T. cruzi. The seroprevalence in our sample was 1.0% (95% CI: 0.2%- 5.3%). INTERPRETATION: We found a low sero-prevalence of Chagas' disease in a community sample of Latin American immigrants and refugees. Physicians who treat Latin American immigrants should consider the risk profile and clinical status of the individual in their decision to screen for Chagas' disease.
BACKGROUND: Chagas' disease is caused by infection with the protozoan agent Trypanosoma cruzi. An estimated sixteen to eighteen million people are infected in Latin America. Outside of endemic regions, Chagas' disease may be transmitted through the transfusion of infected blood components, congenital infection and organ transplantation. We sought to determine the sero-prevalence of antibodies to T. cruzi in a community sample of Latin American refugees and immigrants to Canada. METHODS: This was a sero-prevalence study in Latin American refugees and immigrants living in Canada. Eligible subjects were born in South America, Central America or in Mexico. Participants were recruited from a variety of community settings, as well as from medical clinics. Serum was tested by enzyme-linked immunoassay for antibodies to T. cruzi. RESULTS: A total of 102 participants were enrolled. One sample tested positive for antibodies for T. cruzi. The seroprevalence in our sample was 1.0% (95% CI: 0.2%- 5.3%). INTERPRETATION: We found a low sero-prevalence of Chagas' disease in a community sample of Latin American immigrants and refugees. Physicians who treat Latin American immigrants should consider the risk profile and clinical status of the individual in their decision to screen for Chagas' disease.
Authors: V J Barrett; D A Leiby; J L Odom; M M Otani; J D Rowe; J T Roote; K F Cox; K R Brown; J A Hoiles; A Saez-Alquézar; J F Turrens Journal: Am J Clin Pathol Date: 1997-11 Impact factor: 2.493
Authors: J Llenas-García; A Hernando; S Fiorante; D Maseda; M Matarranz; E Salto; R Rubio; F Pulido Journal: Eur J Clin Microbiol Infect Dis Date: 2012-01-19 Impact factor: 3.267
Authors: Margaret A Fearon; Vito Scalia; Mary Huang; Irene Dines; Momar Ndao; Philippe Lagacé-Wiens Journal: Can J Infect Dis Med Microbiol Date: 2013 Impact factor: 2.471
Authors: Momar Ndao; Terry W Spithill; Rebecca Caffrey; Hongshan Li; Vladimir N Podust; Regis Perichon; Cynthia Santamaria; Alberto Ache; Mark Duncan; Malcolm R Powell; Brian J Ward Journal: J Clin Microbiol Date: 2010-01-13 Impact factor: 5.948
Authors: Pierre Buekens; Olivia Almendares; Yves Carlier; Eric Dumonteil; Mark Eberhard; Rubi Gamboa-Leon; Mark James; Nicolas Padilla; Dawn Wesson; Xu Xiong Journal: Matern Child Health J Date: 2007-06-30
Authors: Natasha S Hochberg; Ruth N Moro; Anandi N Sheth; Susan P Montgomery; Frank Steurer; Isabel T McAuliffe; Yun F Wang; Wendy Armstrong; Hilda N Rivera; Jeffrey L Lennox; Carlos Franco-Paredes Journal: PLoS Negl Trop Dis Date: 2011-04-12
Authors: Pedro E A A Brasil; Liane De Castro; Alejandro M Hasslocher-Moreno; Luiz H C Sangenis; José U Braga Journal: BMC Infect Dis Date: 2010-11-25 Impact factor: 3.090